ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month
ImmunityBio Inc (NASDAQ: IBRX)
ImmunityBio Offers Update On Status Of Its Biologics License Application For VesAnktiva
ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as
ImmunityBio Reports 24+ Months Of Median Duration Of Complete Remission Related To Its Bladder Cancer Treatment
Marten Transport, Ltd. (NASDAQ:MRTN) today announced its dry truckload operations have begun hauling dry van products between Mexico and the U.S. with the first load delivering on time, as expected, February 11th.
This
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
ImmunityBio’s Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has
ImmunityBio Announces Results Of Phase 2 Metastatic Pancreatic Cancer Trial At ASCO GI With Median Overall Survival Of 6.3 Months In Patients With Third-Line Disease, More Than Doubling Historical Survival
ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate for patients